Laura Rose Bloxham



Laura represents high growth technology and life sciences companies from inception to exit. She advises entrepreneurs in company formation, venture capital financing, and a variety of corporate and governance matters.

Laura is a founding member of Orrick’s technology companies practice in the Pacific Northwest. She is passionate about working with founders to grow their business at every stage. She serves as a trusted advisor to her clients in multiple capacities: providing strategic advice in the boardroom, designing and executing financing strategies, negotiating complex transactions from venture financings to successful exits, and supporting day-to-day legal needs of executive teams.

She represents companies and their investors in a variety of verticals, including automotive and logistics (Civil Maps, Convoy, Getaround), consumer applications (AppSheet, Life360, Mylio), financial technology (Credible Labs, Ladder Financial, SoFi), information security (Critical Informatics, Zimperium) and life sciences (Cortexyme, Inmedix), among others.

Prior to joining Orrick, Laura worked in New York as a leveraged finance attorney at Milbank, and in-house at Goldman Sachs and the New York Stock Exchange. In addition to start-up representation, she regularly provides pro bono legal advice to charitable organizations regarding non-profit incorporation and tax exemption applications. (d/b/a Two Tap)
    • $9.5 million sale to Honey
    • $19.3 million Series A financing
    • Acquisition by Google
    • $8.8 million Series A financing
    • $22.5 million Series B financing
    CI Security
    • $6.4 million Series A financing
    • $16 million Series B financing
    • $185 million Series C financing
    • $400 million Series D financing
    • $76.9 million Series B financing
    • $75 million IPO on NASDAQ
    • $50.9 million IPO on ASX
    • $2.5 million Series Seed financing
    • $300 million Series D financing
    • $300 million acquisition of Drivy
    • $18.1 million Series A financing
    Ladder Financial
    • $30 million Series B financing
    • $28 million Series D financing
    • $120.1 million IPO on ASX
    • $230 million Series C investment in Psiquantum
    • $70 million Series F investment in BlueVine
    • $10 million Series B investment in Skedulo Holdings, Inc
    • $25 million Series B investment in Syntiant
    Oisin Biotechnologies
    • $3 million Safe financing
    • $3 million Seed financing
    Social Finance (d/b/a SoFi)
    • General corporate advisement on its $1.2 billion acquisition of Galileo
    Solfice Research (d/b/a Civil Maps)
    • $9.4 million Series A financing
    Varian Medical Systems
    • $140 million Series B investment in Fusion Pharmaceuticals